Inflammatory bowel disease therapy - Roche/Synlogic
Latest Information Update: 24 Jun 2021
At a glance
- Originator Synlogic
- Developer Roche; Synlogic
- Class Anti-inflammatories; Bacteria; Gene therapies
- Mechanism of Action Bacteria replacements; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Inflammatory bowel diseases